Regresar

Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual

Abstract:

OBJECTIVE: To report a case of a microprolactinoma in a male-to-female transsexual treated with estrogens and cyproterone acetate. DESIGN: Case report. SETTING: Endocrinology unit in a university hospital. PATIENT(S): A 33-year-old male-to-female transsexual with prolactin level of 10 ng/mL. INTERVENTION(S): Treatment with equine-conjugated estrogens (2.5 mg/day, orally) and cyproterone acetate (100 mg/day, orally) during 6 months. MAIN OUTCOME MEASURE(S): Her levels of prolactin were repeatedly found to be elevated to a maximum of 133 ng/mL, and magnetic resonance imaging (MRI) revealed a pituitary mass of 5 × 4 × 4 mm. RESULT(S): Discontinuation of the cross-sex hormone treatment did not reduce the levels of prolactin. The use of dopaminergic-agonist therapy normalized them and reduced the size of the microadenoma. After sex-reassignment surgery, she was treated with low-dose …